B
Bull
Bull · 25%NVS
$136.39
Scenario price
$153.810
-0.831 (-0.54%)At close
Loading chart…
- High
- 154.565
- Open
- 154.510
- VWAP
- 153.72
- Vol
- 1.17M
- Mkt Cap
- 217.41B
- Low
- 152.770
- Amount
- 179.21M
- EV/EBITDA, TTM
- 12.62
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
AI analysis of Novartis AG (NVS)
holdNovartis AG is currently trading at $153.81, with a forward P/E of 17.64, indicating potential value. However, the RSI is at 39.45, suggesting the stock is nearing oversold territory, which may present a buying opportunity. The stock has seen a 3.18% decline over the past five days, which could be a concern for short-term investors. The main risk is highlighted by the analyst from Bernstein, who anticipates annual sales declines between 2031 and 2036, which could impact long-term growth.
Analyst Ratings (3)
-16.94% downside
Hold
1 Buy
2 Hold
0 Sell
Current: 153.81
Low
112.00
Average
127.75
High
143.00
Citi
Buy
—
2026-07-22
Citi
2026-07-22
Price Target
—
Buy
Morgan Stanley
Overweight
$170
2026-03-26
Morgan Stanley
2026-03-26
Price Target
$170
Overweight
BofA
Buy
$178
2026-03-23
BofA
2026-03-23
Price Target
$178
Buy
Bernstein
Market Perform
—
2026-03-19
Bernstein
2026-03-19
Price Target
—
Market Perform
HSBC
Reduce
$95
2026-03-17
HSBC
2026-03-17
Price Target
$95
Reduce
Valuation Metrics
The current forward P/E ratio for Novartis AG (NVS) is 17.64, compared to its 5-year average forward P/E of 13.19.
Alphio AI Price Scenarios for NVS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NVS
Events Timeline
News
8.508-22FoolIonis Pharmaceuticals: Silencing Disease at the Source
8.508-16FoolLakers Sold for $12.5 Billion, Achieving 25% ROI
8.508-14FoolInternational Stock ETFs May Lead AI Boom Gains
8.508-14NASDAQ.COMVanguard Predicts International Stocks to Outperform U.S. Growth Stocks
2.008-07NASDAQ.COMBiotech Sector Update: Approvals, Layoffs, and Deals
NVS FAQ — answered by Alphio AI
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Novartis AG is currently trading at $153.81, with a forward P/E of 17.64, indicating potential value. However, the RSI is at 39.45, suggesting the stock is nearing oversold territory, which may present a buying opportunity. The stock has seen a 3.18% decline over the past five days, which could be a concern for short-term investors. The main risk is highlighted by the analyst from Bernstein, who anticipates annual sales declines between 2031 and 2036, which could impact long-term growth.
3 analysts cover NVS: 1 rate it Buy, 2 Hold and 0 Sell. The average price target is 127.75.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.